cardiac enzyme in emergency medicine

Acute chest pain is an important and frequently occurring symptom in patients. chest pain is often a sign of ischemic heart disease. chest pain due to suspected acute coronary syndrome (acs) is responsible for a large and increasing number of hospital attendances and admissions. current practice for suspected acs involves troponin testing 10–12 hours after symptom onset to diagnose myocardial infarction (mi). patients with a negative troponin can be investigated further with computed tomographic coronary angiography (ctca) or exercise electrocardiography (ecg).a review of cardiac biomarkers as screening test in acute chest pain over 15 years was conducted. separate searches were under taken for biomarkers. we searched electronic databases up to 2004-2014, reviewed citation lists and contacted experts to identify diagnostic and prognostic studies comparing a relevant index test (biomarker, ctca or exercise ecg) to the appropriate reference standard. we classified studies to two part early rise biomarkers, high sensitivity biomarkers.conclusion: although presentation troponin has suboptimal sensitivity, measurement of a 10-hour troponin level is unlikely to be cost-effective in most scenarios compared with a high sensitivity presentation troponin. measurement of cardiac troponin using a sensitive method was the best test for the early diagnosis of an acute myocardial infarction (ami). measurement of myoglobin or creatine kinase-mb (ck-mb) in addition to a sensitive troponin test is not recommended. heart-type fatty acid-binding protein (h-fabp) shows promise as an early marker and requires further study.